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Background: The purpose of the present study was to analyze the recurrence pattern of high-grade glioma treated
with a multimodal treatment approach and to evaluate whether the MIB-1 labeling index (LI) could be a useful
marker for predicting the pattern of failure in glioblastoma (GB).
Methods and materials: We evaluated histologically confirmed 131 patients with either anaplastic astrocytoma
(AA) or GB. A median dose was 60 Gy. Concomitant and adjuvant chemotherapy were administered to 111 patients.
MIB-1 LI was assessed by immunohistochemistry. Recurrence patterns were categorized according to the areas of
recurrence as follows: central failure (recurrence in the 95% of 60 Gy); in-field (recurrence in the high-dose volume
of 50 Gy; marginal (recurrence outside the high-dose volume) and distant (recurrence outside the RT field).
Results: The median follow-up durations were 13 months for all patients and 19 months for those remaining alive.
Among AA patients, the 2-year progression-free and overall survival rates were 23.1% and 39.2%, respectively, while
in GB patients, the rates were 13.3% and 27.6%, respectively. The median survival time was 20 months for AA
patients and 15 months for GB patients. Among AA patients, recurrences were central in 68.7% of patients; in-field,
18.8%; and distant, 12.5%, while among GB patients, 69.0% of recurrences were central, 15.5% were in-field, 12.1%
were marginal, and 3.4% were distant. The MIB-1 LI medians were 18.2% in AA and 29.8% in GB. Interestingly, in
patients with GB, the MIB-1 LI had a strong effect on the pattern of failure (P = 0.014), while the extent of surgical
removal (P = 0.47) and regimens of chemotherapy (P = 0.57) did not.
Conclusions: MIB-1 LI predominantly affected the pattern of failure in GB patients treated with a multimodal
approach, and it might be a useful tool for the management of the disease.
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Glioblastoma (GB) is one of the most aggressive primary
brain tumors. The standard treatment includes a multi-
modal approach with surgery, radiotherapy, and chemo-
therapy. Although concurrent chemoradiotherapy with
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reproduction in any medium, provided the orfor GB [1], the overall outcome for GB has not improved
significantly, and intracranial tumor recurrence or pro-
gression develops in most patients in less than 1 year.
"The nature of GB, with widespread tumor infiltration
and lower radiosensitivity, has frustrated efforts to pro-
vide durable tumor control with radiotherapy." Although
several investigators demonstrated the presence of wide-
spread microscopic infiltration within the brain [2], local
recurrence predominates with this disease, most often
within 2 cm of the original tumor. Conformal radiother-
apy that includes postoperative peritumoral edema in the
target volume is currently being used in the RadiationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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0525 and RTOG 8525 trials). Alternatively, treatment
strategies based on contrast-enhancement of the tumor
(using CT/MRI) plus 2-cm margins is currently
employed in many European institutions, according to
the European Organization for Research and Treatment
of Cancer (EORTC) recommendations [3-6]. Therefore,
consensus guidelines for clinical target volume (CTV)
delineation remain controversial. On the contrary, with
respect to radiation doses, although prescribed doses of
60 Gy are generally employed, attempts at dose escal-
ation or altered fractionation of radiotherapy have been
widely challenged [7,8]. Dose escalation to 90 Gy [7] or
the addition of a stereotactic radiosurgery (SRS) boost
[9] may reduce the failure rates in the high-dose region,
although recurrence then tends to occur just outside the
high-dose region.
Determination of proliferative activity using the mono-
clonal antibody MIB-1 labeling index (LI) has been
investigated in malignant gliomas [10,11]. Although
some studies indicated that MIB-1 LI was correlated
with an increasing grade of malignancy, no study has
evaluated whether MIB-1 LI might predict a pattern of
failure in GB patients.
We evaluated the outcome of high-grade glioma trea-
ted with a multimodal approach, and investigated pat-
terns of failure with regard to MIB-1 LI. The purpose of
this study was to analyze the recurrence patterns and to
evaluate whether MIB-1 LI could be useful as a marker
to predict the pattern of failure in high-grade glioma.
Materials and methods
Patients
In this study, 142 consecutive patients with histologically
proven high-grade glioma, i.e., anaplastic astrocytoma
(AA) or GB, were retrospectively reviewed. These patients
were treated with radiotherapy at Kobe University Hospital
or Hyogo Cancer Center between 2000 and 2010. The
retrospective review and the use of clinical data were
approved by the institutional ethics board. Eleven patients
were not included in the analysis: 5 patients who were
treated with palliative therapy, 5 patients who discontinued
the course of radiotherapy, and 1 patient who refused to
enroll in the study. Therefore, a total of 131 patients were
included in the analysis. Written informed consent was
obtained from the patient for publication of this case re-
port and any accompanying images.
Extent of surgical removal
The extent of surgical removal was assessed using surgi-
cal information and/or the comparison of preoperative
and postoperative magnetic resonance imaging (MRI).
The extent of surgical removal was categorized into 4
subgroups: gross total removal (GTR), subtotal removal(STR), partial removal (PR), and biopsy. GTR was
defined as a resection of more than 99% of tumor vol-
ume; STR, a resection of 80–99% of tumor volume; PR,
as a resection of 20–80% of tumor volume; and biopsy, a
resection of less than 20% of tumor volume.
Methods of radiation therapy
Radiotherapy was started 2–4 weeks after surgery. Treat-
ment planning computerized tomography (CT) scans
obtained images at 2.5–5.0-mm slice intervals. Informa-
tion obtained in the simulation CT scan was combined
with any available MRI data, including post-contrast T1-
and T2-weighted images or fluid-attenuated inversion re-
covery (FLAIR) images as fusion images. For the plan-
ning of radiotherapy, FOCUS (2000–2004) or Xio
software (2005–2010) (CMS Co. Ltd., Japan) was used.
The gross tumor volume (GTV) was carefully defined
considering gadolinium-enhanced lesions in presurgical
MRI and/or residual tumor lesions in post-surgical MRI.
In our methods, the GTV was basically defined based on
pre-surgical tumor extents. However, in case that range
and portion of surgical cavities was beyond the pre-
surgical tumor extents. The GTV were reconstructed by
pre-surgical tumor extents combined with post-surgical
imaging, because to set GTV from only presurgical
images was considered to be insufficient. The CTV for
the initial plan was delineated, including the area of peri-
tumoral edema (high-intensity lesion on FLAIR images)
plus the 1.5–2.0-cm margin, and the CTV-boost was
defined based on the GTV with a 1.5–2.0-cm margin.
For the setup margin, a 5-mm margin was applied to
each CTV (CTV-initial, CTV-boost) to create PTVs
(PTV-initial, PTV-boost). All patients were treated with
conventional fractions of 1.8–2.0 Gy 5 times a week. A
median total dose of 60 Gy (range: 54–71.2 Gy) was
delivered in 27–39 fractions with concomitant and adju-
vant chemotherapy. The prescribed dose was 40–50.4 Gy
to the PTV-initial for both AA and GB, followed by 10–
20.8 Gy to the PTV-boost. The 100% isodose line was
defined at the isocenter, and the dose was prescribed to
this point. All patients were treated with three-
dimensional conformal radiation therapy consisting of
3–5 non-coplanar fields. The normal tissues delineated
included the optic nerves, optic chiasm, brainstem, eye,
and optic lens. The optic nerve and optic chiasm max-
imum doses were restricted to ≤50 Gy. The maximum
dose to the brainstem was restricted to ≤54 Gy.
Chemotherapy
Regimens of chemotherapy shifted according to the study
period. Between September 2000 and September 2006, 55
patients received a combination regimen that consisted of
ACNU (nimustine), vincristine, and interferon with radio-
therapy. After October 2006, 56 patients were scheduled
Table 1 Patient characteristics and treatments (n = 131)
Characteristics
Anaplastic astrocytoma Glioblastoma
n=26 (%) n=105 (%)
Age
Median 52.5 years 59 years
(range) (18–75 years) (16–77 years)
Sex
Male 14 (54) 59 (56)
Female 12 (46) 46 (44)
Original tumor location
Frontal lobe 11 (42) 36 (34)
Temporal lobe 5 (19) 35 (33)
Parietal lobe 3 (12) 20 (19)
Thalamus 4 (15) 3 (3)
Occipital 1 (4) 6 (6)
Cerebellum 2 (8) 2 (2)
Basal ganglia 0 (0) 2 (2)
Brainstem 0 (0) 1 (1)
MIB-1 labeling index
Median (range) 18.2% (2–35) 29.8% (2–80)
Radiotherapy
Median dose 60 Gy 60 Gy
(range) (54–68.4 Gy) (54–71.2 Gy)
Extent of surgical removal
Gross total removal 3 (12) 18 (17)
Subtotal removal 5 (19) 15 (14)
Partial removal 11 (42) 59 (56)
Biopsy only 7 (27) 13 (12)
Chemotherapy
ACNU (Nimustine) 11 (42) 44 (42)
Temozolomide 11 (42) 45 (43)
None 4 (15) 14 (13)
Unknown 0 (0) 2 (2)
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dosage of 75 mg/m2/day followed by adjuvant therapy at a
dosage of 150–200 mg/m2/day for 5 days every 28 days,
unless the disease progressed or the patient experienced
treatment-related toxicity or declining performance status
necessitating the discontinuation of chemotherapy. In our
policy, concomitant chemotherapy was considered to all
patients with AA and with GB. However, 4 (15%) patients
with AA could not receive chemotherapy because of their
poor general conditions. Thus, 111 (84.7%) patients
received chemotherapy.
Immunohistochemical analysis
Paraffin-embedded tissue blocks were sectioned (4-μm
thick) onto slides and then deparaffinized. Sections were
immunostained using the Vectastain ABC Elite Kit (Vec-
tor Laboratories, Burlingame, CA, USA) according to the
manufacturer’s instructions with anti-MIB-1 monoclonal
antibody. The MIB-1 LI was calculated as the percentage
of positively stained tumor cell nuclei among 1000 nuclei
detected in areas with the greatest degree of immunos-
taining [11]. A median of the MIB-1 LI was used as
reference to establish a cut off point [12].
Recurrence diagnosis methods
The diagnosis of tumor recurrence and disease progres-
sion was made using MRI. Positron emission tomog-
raphy (PET) imaging was not routinely used. Recurrence
was defined as follows: central failure if more than 95%
of the recurrence volume was in the 95% isodose line of
60 Gy (boost volume); in-field if more than 95% of the
recurrence volume was in the high-dose volume (50 Gy);
marginal when less than 95% of recurrence volume was
outside the high-dose volume; distant when recurrence
was outside the RT field (<20% isodose line).
Assessment of the pattern of failure
There were 43 patients (8 AA patients and 35 GB
patients) who showed no sign of recurrence. Among 88
patients who experienced recurrence, 14 patients’ sam-
ples were not submitted for immunohistochemical evalu-
ation because of insufficient samples. In total, data from
74 patients (16 AA patients and 58 GB patients) were
evaluated for the pattern of failure in this study.
Follow-up evaluation and statistical analyses
In the follow-up evaluations, local and systemic tumor
control was assessed at 1–3-month intervals using MRI.
Progression-free survival (PFS) and overall survival (OS)
rates were analyzed statistically in all patients. PFS was cal-
culated from the first day of radiotherapy to the date of
any recurrence or death, or censored the date of the last
follow-up. OS was calculated from the first day of radio-
therapy to the date of death, or censored the date of thelast follow-up, and calculations were made using Kaplan–
Meier estimates. Statistical significance was determined
using the log-rank test. The chi-square test was used for
the comparisons among cohorts in this analysis. Variables
influencing OS and PFS were evaluated with multivariate
Cox proportional hazards model with a 95% confidence
interval. Differences were considered statistically signifi-
cant at P values< 0.05. All statistical analyses were per-
formed using StateView (version 5.0).
Results
Patients and treatments
Patient and treatment details are shown in Table 1.
Twenty-six (20%) patients had AA, and 105 (80%)
Table 2 Patterns of recurrence after multimodal




n=16 (%) n= 58 (%)
Central 11 (68.7) 40 (69.0)
In-field 3 (18.8) 9 (15.5)
Marginal 0 (0) 7 (12.1)
Distant 2 (12.5) 2 (3.4)
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differences between the 2 cohorts with regard to radio-
therapy methods, the extent of surgical removal, or
chemotherapy regimens.Progression-free and overall survival
The median follow-up periods were 13 months for all
patients and 19 months for those remaining alive.
Among AA patients, the 2-year PFS and OS rates were
23.1% and 39.2%, respectively, while in GB patients,
the rates were 13.3% and 27.6%, respectively (Figure 1).
The median survival times (MSTs) were 20 months in
patients with AA and 15 months in patients with GB.
The cause of death among AA patients was identified
as primary tumor deterioration in 17 patients (100%),
while causes of death in GB cases were identified as
primary tumor deterioration in 75 patients (93.8%),
other diseases (pneumonia) in 4 patients (5%), and un-
known in one patient (1.2%). Among 105 patients with
GB, except for 16 patients who did not receive chemo-
therapy or unknown, 44 (42%) patients were treated
with ACNU-based regimens during 2000 to SeptemberFigure 1 Kaplan-Meier curves of overall survival and progression-free
progression-free survival (PFS) and overall survival (OS) according to histolo2006, and 45 (43%) patients were treated with TMZ-
based regimens in between October 2007 to thereafter
(Table 1). Between ACNU-based and TMZ-based
groups with GB, there were no significant difference in
OS (P =0.86) and PFS (P =0.42), and in. In patients
with AA, the tendency was similar, resulting in OS
(P =0.93) and PFS (P =0.72).
Patterns of failure for AA or GB
Among the AA patients, 11 (68.7%) displayed recurrence
in the central area, while 3 (18.8%) displayed recurrence
in the in-field area and 2 (12.5%), in the distant area
(Table 2). Among 5 patients who displayed recurrence
outside of the central area, 1 (20%) patient also had a re-
current tumor in the central area. In contrast, among
patients with GB, 40 (69.0%) displayed recurrence in the
central area, while 9 (15.5%) displayed recurrence in the
in-field area; 7 (12.1%), in the marginal area; and 2
(3.4%), in the distant area (Table 2). Among those 18
patients whose recurrence was outside of the central
area, 6 (33%) patients also had a recurrent tumor in the
central area. Representative cases of recurrent tumors
observed in the central and distant areas are shown in
Figure 2 and Figure 3, respectively.
Distribution of MIB-1 LI
MIB-1 LI scores were available in 101 patients (22 AA
patients and 79 GB patients). The MIB-1 LI of AA
was comparatively low, and the median MIB-1 LI was
18.2% (range: 2–35%). In contrast, the MIB-1 LI of
GB was higher and more widely distributed. The me-
dian MIB-1 LI was 29.8% in GB (range: 2–80%)
(Figure 4).survival for each histological grade. Kaplan-Meier curves of
gy grade: (A) anaplastic astrocytoma (n = 26), (B) glioblastoma (n = 105).
Figure 2 Representative images for the case of GB with lower MIB-1 LI. A 76-years female patient with GB showing a lower MIB-1 LI (21%)
that recurred in the central region. (A) A postcontrast MR image (T1 weighted) before surgery. (B) A postcontrast MR image (T1 weighted) after a
gross total removal. (C) Treatment planning CT image showing the 95% isodose curve (yellow), the 80% isodose curve (green), and the 20%
isodose curve (blue). (D) A postcontrast MR image (T1 weighted) at 4 months after completing radiotherapy showing a recurrence tumor that
developed in the central. (E) Immunohistochemical analyses (×200).
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Of the 131 patients, 101 patients (16 AA patients and
58 GB patients) were available for evaluation of recur-
rence pattern and MIB-1 LI. Other 27 patients had
not yet shown signs of tumor recurrence. Among the
GB patients, recurrence occurred central area and
others in 25 (83%) and 5 (17%) of patients with the
MIB-1 LI <30%, and in 15 (54%) and 13 (46%) of
patients with the MIB-1 LI ≥ 30%, respectively
(P = 0.014) (Table 3) In contrast, among the AA
patients, recurrence occurred central area and others(in-field, marginal, or distant) in 9 (69%) and 4 (31%)
of patients with the MIB-1 LI< 30%, and in 2 (67%)
and 1 (33%) of patients with the MIB-1 LI ≥ 30%, re-
spectively (P = 0.931).
For patients with GB whose MIB-1 LI was< 30%, 25
(83%) developed a central recurrence, whereas 15 (54%)
for those with MIB-1 LI ≥ 30% (P = 0.014). Among
patients with the MIB-1 LI< 30% who recurred in the
other sites, there were 2 (7%) patients in the in-field, 3
(10%) patients in the marginal, and none in the distant,
whereas those with MIB-1 LI ≥ 30%, there were 7 (25%)
Figure 3 Representative images for the case of GB with higher MIB-1 LI. A 24-years male patient with GB showing a higher MIB-1 LI (79%)
that recurred in the distant region. (A) A postcontrast MR image (T1 weighted) before surgery (B) A postcontrast MR image (T1 weighted) after a
gross total removal. (C) Treatment planning CT image showing the 95% isodose curve (yellow), 80% isodose curve (green), and the 20% isodose
curve (blue). (D) A postcontrast MR image (T1 weighted) at 11 months after completion of radiation showing a recurrence tumor that developed
in the distant. (E) Immunohistochemical analyses (×200).
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and 2 (7%) patients in the distant, respectively.
In patients with GB, the MIB-1 LI was strongly
affected by the pattern of failure (P = 0.014), while the
extent of surgical removal (P = 0.47) or regimens of
chemotherapy (P = 0.57) were not (Table 3). In con-
trast, in patients with AA, the MIB-1 (P = 0.93), extent
of surgical removal (P = 0.84), and regimens of chemo-
therapy (P = 0.61) did not influence the pattern of
failure.Evaluation of prognostic factor for OS and PFS
Results of univariate and multivariate analysis of prog-
nostic factors were shown (Table 4). In the multivariate
analysis, age (P = 0.04), performance status (P< 0.01)
and extent of resection (P = 0.04) were significant prog-
nostic factors for OS. In case of PFS, performance sta-
tus (P = 0.01) was the single significant prognostic
factor. Om the contrary, MIB-1 LI was not significant
factor for OS or PFS in both univariate and multivari-
ate analyses.
Figure 4 Distributions of MIB-1 LI. Distributions of MIB-1 LI in patients with AA (n = 22) and in patients with GB (n = 79).
Uehara et al. Radiation Oncology 2012, 7:104 Page 7 of 11
http://www.ro-journal.com/content/7/1/104Discussion
In the management of GB, the pattern of failure is one
of the major concerns in relation to the CTV margins,
optimal radiation dose, and identification of biomarkers.
However, the factors affecting the pattern of failure in
GB have not been described in detail. The present study
is the first to report an association between the MIB-1 LI
and the pattern of failure in patients with GB.
In prior studies, treatment factors, including CTV
margins, radiation dose, and chemotherapy, were widely
discussed as the most important aspects determining the
pattern of failure of GB [3-5,7,13-15]. Chang et al. [3], in
a study based on protocols following RTOG guidelines,
conducted at the M.D. Anderson Cancer Center,
reported similar patterns of failure in a series of 48 GB
patients by comparing treatment plans based on residual
tumor and resection cavity plus 2-cm margins. Liang
et al. [4] studied 42 patients with malignant glioma irra-
diated with 60 Gy using conformal radiation techniques.
All patients developed recurrences within 2 cm of the
original tumor. Lee et al. [5] analyzed 36 patients withTable 3 Factors may or may not affect the patterns of failure
Patients with glioblastoma
MIB-1 (n =58) Extent of su
Sites of < 30 ≧ 30 P value > 80%
recurrence
n = 30 n = 28 n = 20
Central 25 15 0.014 15
Others * 5 13 5
Patients with anaplastic astrocytoma
MIB-1 (n =16) Extent of su
Sites of < 30 ≧ 30 P value > 80%
recurrence
n = 13 n = 3 n= 5
Central 9 2 0.93 3
Others * 4 1 2
* Others = In-field +marginal + distant.
†> 80%=GTR or Sub-total, < 80%=Partial/Biopsy.high-grade astrocytoma treated with 70 Gy and 80 Gy to
a CT/MRI-localized PTV (tumor size: <2–3 cm) and
found that 89% of the recurrences occurred with a cen-
tral or in-field recurrence pattern. McDonald et al. [13]
demonstrated that through the use of limited margins,
92% of the patients in their series had a PTV boost mar-
gin of 1 cm or less, only 5% of patients had a marginal
failure, and 2% patients had a distant failure with temo-
zolomide chemoradiation. Minniti et al. [14] demon-
strated that the majority of patients treated with RT plus
concomitant and adjuvant temozolomide have central
recurrences, while distant new lesions may occur in
more than 10% of patients. Milano et al. [15] demon-
strated that central recurrence of glioblastoma treated
with radiation and temozolomide predominates and per-
sists over time, whereas new in-field, marginal, and dis-
tant recurrences commonly develop, particularly at later
time points in patients with longer survival. Our results
regarding the proportions of particular sites of recur-
rence were consistent with those reports (Table 5). Al-
though the reports cited above included different CTVin patients with glioblastoma or anaplastic astrocytoma
rgical removal (n =58) Chemotherapy (n =53)
< 80% P value ACNU TMZ P value
based based
n = 38 n= 23 n= 30
25 0.47 17 20 0.57
13 6 10
rgical removal (n =16) Chemotherapy (n =13)
< 80% P value ACNU TMZ P value
based based
n = 11 n = 5 n= 8
8 0.61 4 6 0.84
3 1 2
Table 4 Results of univariate and multivariate analyses for OS and PFS in patients with glioblastoma or anaplastic
astrocytoma
Variable Test for favorable status OS PFS
Univariate analysis P value P value
PS 0,1 (n = 60) vs. 2,3, and 4 (n = 60) <0.01 <0.01
Age < 50 (n = 37) vs. ≧ 50 (n = 94) 0.04 0.08
Extent of resection GTR/STR (n = 41) vs. PR/biopsy (n = 90) 0.06 0.37
Histological grade AA (n = 26) vs. GB (n = 105) 0.08 0.11
MIB-1 LI < 30 (n = 61) vs. ≧ 30 (n = 43) 0.21 0.59
BED or Radiation dose ≤ 72 GyE (n = 77) vs. > 72 GyE (n = 54) 0.29 0.53
Gender Male (n = 73) vs. Female (n = 58) 0.73 0.54




Extent of resection 0.04 0.30
MIB-1 LI 0.07 0.12
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the patterns of failure of GB appear to be similar, sug-
gesting that these treatment factors might not strongly
affect the pattern of failure in GB.
Several clinical values of MIB-1 LI have been reported
in human gliomas [10,11,17,18]. Johnnessen and Torp
[10] evaluated the clinical usefulness of MIB-1 LI in
grading for glioma, based on a review of 16 studies in-
cluding a total of 915 patients. In addition, MIB-1 LI can
be considered as an important proliferation parameter,
and may be associated with clinical growth parameters
independent of other prognostic factors in gliomas. Sev-
eral cut-off studies have observed a significant correl-
ation between MIB-1 LI and postoperative survival inTable 5 Comparison of published data with regard to pattern
Author Year Number Treatment D(
Nakagawa [7] 1998 38 3DCRT+ACNU 6
Lee [5] 1999 36 3DCRT 7
Chan [6] 2002 34 3DCRT
Chang [3] 2007 48 3DCRT± chemo*
Brandes [16] 2009 95 3DCRT + TMZ
Milano [15] 2010 54 3DCRT + TMZ
Minniti [14] 2010 105 3DCRT + TMZ
McDonald [13] 2011 41 (IMRT or 3DCRT) ± TMZ
This study 2012 58 3DCRT ± (ACNU or TMZ)
*21/48 patients received adjuvant or concurrent chemotherapy (carmustine, procarb
†5% were subependymal recurrences (did not apply to our classification method of
††46% were subependymal recurrences (did not apply to our classification method
}Insufficient data to apply to our classification method of recurrence sites.astrocytic gliomas [17]. However, the majority of studies
to date have failed to confirm such an association be-
tween the MIB-1 LI and survival in patients with GB
[18]. In our series, values of the MIB-1 LI were widely
distributed in both GB and AA cohorts. Median of the
distribution in GB (cut off = 30) were first evaluated for
correlation with patterns of failure, and other cut off
points (cut off = 10, 20, 35, and 50) were also assessed.
Among those cut off points, the cut off = 30 was found
to be the only significant value as for the pattern of fail-
ure in GB. On the contrary, any cut-off point did not
have useful values in AA. The discrepancy between GB
and AA might be a matter of debate. It is at least specu-






Central In-field Marginal Distant
0–80 0–2 90%† 5%
90 0–2 46%†† 8%
0–80 1.5 72% 17% 8% 3%
90 0.5 78% 13% 9%
60 1 83% 6% 6% 4%
60 2–3 72% 6% 22%
60 2–2.5 92%} 15% 13%
60 1–2 79% 6% 6% 14%
60 0.8 78% 15% 5% 2%
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(2 - 80%). Therefore, to set cut off might be difficult. Of
course, other possibilities might be raised. This issue
should be discussed more with accumulation of reports.
Notably, our results indicated that the MIB-1 LI
affected the pattern of failure in patients with GB, while
the extent of surgical removal or chemotherapy regimens
did not (Table 3). Previously, Shibamoto et al. [19]
demonstrated that extent of surgery was associated with
the prognosis of GB in their analysis of 178 cases. How-
ever, there are no reports demonstrating that MIB-1 LI
can provide clues for the recognition of the pattern of
failure in patients with high-grade glioma. Thus, to our
knowledge, this report is the first to show the clinical
value of the MIB-1 LI in GB. On the contrary, in patients
with AA, no association between MIB-1 and the pattern
of failure was observed. Several reasons may explain this
result. Because AA is less aggressive than GB, MIB-1 LI
did not reflect disease behavior in AA. In addition, the
number of patients with AA was quite small. Therefore,
although our findings might be restricted to GB patients,
they are valuable in elucidating novel aspects of GB. Be-
cause MIB-1 LI is known to be influenced by both the
staining and counting methods, inter-laboratory and
inter-observer variability need to be carefully determined
[20]. Moreover, in addition to the grading system or
prognostic significance, the cut-off value of MIB-1 LI for
the pattern of failure in GB remains to be examined.
Therefore, the present findings should be confirmed by
larger-scale and multi-institutional studies with standar-
dized evaluation methods for MIB-1 LI.
The MIB-1 LI had the impact in prediction of POF when
sites of recurrence were stratified to the central versus
others as shown in the Table 3. When the stratification
was converted to the subgroups of the central or the in-
field versus of the marginal or the distant, the value was
not significant (P= 0.23). That might suggest that the
MIB-1 with a cut-off = 30 was closely involved the in-field
recurrence. Of course, other factors, such as definition of
GTV (pre-surgical or post-surgical), margins for CTV, and
total dose, should be standardized before proposing the as-
sociation between the MIB-1 LI and the in-field recur-
rence, this result need to be clarified in the future study.
It is difficult to state distinct association between
radiosensitivity and the MIB-1 LI in GB. As far as we
investigated, there are no reports elucidating the direct
link in GB. Possible explanation might be that, not only
the MIB-1 LI, GB has been reported to contain several
abnormalities of molecular parameters, including 1p19q
deletion status [21,22], isocitrate dehydrogenase (IDH)
genes mutation status [23,24], or methylation status of
the O6-methylguanine-DNA methyltransferase gene
MGMT promoter methylation status [25-27]. On the
contrary, increased cell cycling and MIB-1 LI suggestmore aggressive behavior of promote tumor progression
and metastasis in variety of cancers [28,29]. Therefore,
the MIB-1 with association with other molecular para-
meters might reflect tumor behavior and POF in patients
with GB. Although the MIB-1 LI could be a useful tool
to recognize disease characteristics including POF, fur-
ther clinical and experimental studies are warranted.
From our result, it is possible to propose that patients
with low MIB-1 LI have a benefit to receive increased
dose of radiotherapy because more often central recur-
rence might occur. On the contrary, patients with the
high MIB-1 LI might not have a benefit because predic-
tion of sites of recurrence were difficult. Therefore, in
those patients with the high MIB-1 LI, more aggressive
chemotherapy seemed to be more important instead of a
dose escalation of radiotherapy. Thus, the MIB-1 LI
could be a useful tool to determine individual strategy in
patients with GB with prediction of POF.
Among other biomarkers for GB, MGMT methylation
seems to be the most intensively examined biomarker
[14,16]. Brandes et al. [16] demonstrated that recurrence
is correlated with MGMT methylation status in patients
who received chemoradiation with temozolomide. Inter-
estingly, Minniti et al. [14] also reported that patterns of
recurrence were significantly different according to the
methylation status of the MGMT promoter. Recurrences
were central/in-field and distant in 64% and 31% of
methylated patients versus 91% and 5.4% of unmethy-
lated patients (P = 0.01), respectively. The present study
did not include an evaluation of MGMT; however, the cor-
relation between MIB-1 LI and MGMT or other markers
and their combination should be examined in future
studies. The combination efficacy between MIB-1 LI and
MGMT could also affect the strategy for GB treatment.
The MIB-1 LI has been used as a marker of the prolif-
eration rate of various intracranial and extracranial
tumors. Okita and coworkers [30] reported that MIB-1 LI
of the recurrent tumors identified as a significant inde-
pendent prognostic factor in their multivariate analysis.
Kim and coworkers [31] reported that the values of MIB-1
LI between primary and recurrent tumors were different,
and that the MIB-1 LIs of the recurrent tumors were
reduced in 75% of patients with GB. Their explanation to
the result was that radiotherapy and/or chemotherapy
might suppress proliferation, actively proliferating tumors,
and they suggest that the MIB-1 LI may play a diagnostic
role in recurrent GB. Thus, the prediction of POF by the
MIB-1 LI will lead to evaluation and comparison between
primary and recurrent tumors, and possibly might illus-
trate tumor characteristics of GB in the future.
Conclusions
The proportions of recurrence sites in our series of AA
and GB were consistent with previous reports addressing
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http://www.ro-journal.com/content/7/1/104patterns of failure in high-grade gliomas. Our novel find-
ings identified MIB-1 LI, but not treatment factors, as a
biomarker that was significantly correlated with the pat-
tern of failure in GB patients. Although the present find-
ings need to be confirmed by larger-scale studies, this
report provides important information to help elucidate
the biological nature of GB.
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